ProCE Banner Activity

IsKia EMN24: Phase III Trial of IsaKRd vs KRd in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Conference Coverage

The addition of isatuximab to carfilzomib, lenalidomide, and dexamethasone (KRd) resulted in higher rates of MRD negativity vs KRd in transplant-eligible patients with newly diagnosed multiple myeloma. 

Released: December 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.